EagleClaw Capital Management’s Genomic Health, Inc. GHDX Stock Holding History

EagleClaw Capital Management’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,900	Closed	-$200K	–	109
2016 Q3	$200K	Buy	+6,900	New	+$192K	0.13%	102
2016 Q1	–	Sell	-7,300	Closed	-$256K	–	109
2015 Q4	$256K	Buy	+7,300	New	+$196K	0.17%	93
2015 Q3	–	Sell	-7,300	Closed	-$203K	–	105
2015 Q2	$203K	Buy	7,300 +500	+7%	+$14.1K	0.13%	102
2015 Q1	$207K	Buy	+6,800	New	+$216K	0.13%	103

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

EagleClaw Capital Management's GHDX Position: Q4 2016 in Review

EagleClaw Capital Management sold out of Genomic Health, Inc. (GHDX) in Q4 2016, closing a stake of 6,900 shares — an estimated $200K sold.

EagleClaw Capital Management first reported a position in GHDX in Q1 2015 and held it in 4 quarters. The position peaked at $256K in Q4 2015. 133 funds tracked by Wall St. Rank hold GHDX as of Q4 2016.

EagleClaw Capital Management reported no remaining Genomic Health, Inc. position as of Q4 2016 after selling out during the quarter.
EagleClaw Capital Management sold 6,900 Genomic Health, Inc. shares in Q4 2016, an estimated $200K.
EagleClaw Capital Management first reported a position in Genomic Health, Inc. in Q1 2015 and held it in 4 quarters.
EagleClaw Capital Management's Genomic Health, Inc. position peaked at $256K in Q4 2015.
133 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2016.

Based on EagleClaw Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.